Notice of Preliminary Results

RNS Number : 7111V

Tissue Regenix Group PLC

20 April 2016

 

Tissue Regenix Group plc

Notice of Preliminary Results

Leeds, 20th April 2016 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group"), the regenerative medical devices company, announces that it will publish its unaudited preliminary results for the year ended 31^st January 2016, on Monday 23^rd May 2016.

A results presentation will be held on the morning of the 23^rd May in London, with corporate and financial updates from CEO Antony Odell, and CFO, Ian Jefferson, as well as guest speaker Dr Francisco da Costa from The Groups research partner, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil.

If you would like to attend, or for further information, please contact [e-mail] 

Tissue Regenix Group plc Caitlin Pearson                                 Corporate Communications Officer	Tel: [phone]
Jefferies International Ltd Simon Hardy / Harry Nicholas	Tel:  [phone]
Tulchan Communications James Macey-White / Matt Low	Tel: [phone]

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

 In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

END

 

 

NOREANLNFAPKEFF